ITCI Earnings Prediction
The chart below shows how ITCI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ITCI sees a -2.74% change in stock price 10 days leading up to the earnings, and a -3.17% change 10 days following the report. On the earnings day itself, the stock moves by +1.12%. This data can give you a slight idea of what to expect for the next quarter's release.
ITCI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
175.38M
39.00%
8.67%
Gross Margin
91.27%
-1.61%
-1.82%
Operating Margin
-22.15%
-5.94%
28.93%
Net Margin
-15.01%
-21.94%
49.35%
EPS
-0.25
-0.00%
56.25%
No Data Available
ITCI Earnings Analysis
Intra-Cellular Therapies Inc. Corporation (ITCI.O) Earnings Conference Call
Positive
Strong Sales Growth: C A P L Y T A's growth trajectory continues to reflect a compelling product profile and our successful commercial execution with net sales of $175.2 million in the third quarter, representing a 39% increase over the third quarter of 2023.
Sales Guidance Increase: Based on this continued strong performance, we are raising our 2024 fully year net sales guidance range to $665 million to $685 million.
Prescription Growth Performance: C A P L Y T A registered another strong performance in Q3 with robust year-over-year growth in total prescriptions of 38% and a sequential quarter-over-quarter growth rate of approximately 9%.
New Prescriber Milestone: During Q3, we added 4,000 new first-time prescribers of C A P L Y T A having now increased that cumulative total since launch to over 49,000 unique prescribers.
R&D Expense Increase: Our R&D expenses for Q3 were $66.8 million compared to $41.6 million for the same period in 2023, reflecting our commitment to advancing our broad pipeline.
Negative
R&D Expense Increase: C A P L Y T A's R & D expenses for Q3 were $66.8 million compared to $41.6 million for the same period in 2023, indicating a significant increase in spending without corresponding revenue growth.
SG&A Expense Increase: Selling, general, and administrative expenses for the third quarter were $132.1 million compared to $105.2 million for the same period in 2023, reflecting a 25.6% increase in costs.
Gross Net Percentage Analysis: The gross net percentage in the quarter was in mid-30s, consistent with expectations, but indicates a potential decline in profitability.
SG&A Expense Guidance Adjustment: Despite a strong performance in Q3, the company is narrowing its fully year SG&A expense guidance range to $490 million to $510 million, suggesting tighter cost controls are needed.
Revised Sales Guidance: The company is raising its 2024 fully year net sales guidance range to $665 million to $685 million, which may indicate previous guidance was overly optimistic.
ITCI FAQs
How does ITCI typically perform around its earnings report dates?
Is Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ITCI Earning Call Sentiment
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ITCI.O
0.35%Positive
The earnings call summary highlights strong financial performance with a 39% YoY increase in net sales and a robust cash position. The company is expanding its sales force and advancing its pipeline, indicating growth potential. Despite regulatory and supply chain risks, the optimistic guidance and increased sales force suggest positive momentum. The Q&A section supports this sentiment, with management expressing confidence in CAPLYTA's market opportunity. Overall, the sentiment is positive, but cautious due to potential risks and uncertainties.
